Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
18 Aug 2025

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
18 Aug 2025

Key insights from head and neck research at ASCO 2025

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA
Key insights from head and neck research at ASCO 2025 ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )
8 Aug 2025

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran
Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )
17 Jul 2025

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
11 Jul 2025

Independent clones in CLL show oligoclonality and early evolution patterns

Dr Ferran Nadeu - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
Independent clones in CLL show oligoclonality and early evolution patterns ( Dr Ferran Nadeu - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain )
10 Jul 2025

Breast cancer survivorship

Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg
Breast cancer survivorship ( Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg )
10 Jul 2025

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi
Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )
10 Jul 2025

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )
9 Jul 2025

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia

Dr Anthony Stein - City of Hope, Duarte, USA
Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )
27 Jun 2025

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )
27 Jun 2025

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )
27 Jun 2025